事关食品安全、电商乱象等，这场发布会信息量很大

Core Viewpoint - The article discusses the achievements and reforms in market regulation during the "14th Five-Year Plan" period, highlighting key areas of focus for improving the business environment and consumer protection in China [1][3]. Group 1: Registration Capital Reform - The revised Company Law stipulates that the maximum period for shareholders to contribute registered capital is five years, effective from July 1, 2024 [5]. - The reform aims to curb market irregularities such as excessive capital contributions and long payment periods, enhancing the credibility of registered capital [5][6]. - The implementation of "real-name registration" and verification of address information is intended to prevent fraudulent registrations and protect creditors' rights [5][6]. Group 2: Prevention of "Minor Offenses with Heavy Penalties" - The regulatory approach emphasizes a fair competition environment to stimulate business innovation and development [8]. - The introduction of a discretionary power baseline for administrative law enforcement aims to reduce unnecessary penalties for minor violations [8]. - A notable case highlighted the issue of disproportionate penalties, leading to a reassessment of enforcement practices [8]. Group 3: Platform Economy Regulation - The platform economy faces challenges such as algorithm abuse and unfair competition, necessitating regulatory oversight [11]. - Regulatory actions have led to the removal of over 4.5 million illegal product listings and the suspension of 58,000 online stores [11]. - Continuous dialogue with major platforms aims to promote compliance and address issues related to unfair practices in the food delivery sector [12]. Group 4: Food Safety Governance - Food safety remains a critical concern, with regulatory bodies enhancing compliance guidance for platform enterprises [14]. - Recent initiatives include the release of a draft regulation to clarify food safety responsibilities for online sales and delivery platforms [14]. - Strict penalties have been imposed for violations, including the revocation of 3,072 licenses and restrictions on 238,000 individuals [15]. Group 5: Accelerating Innovative Drug Review and Approval - Since the beginning of the "14th Five-Year Plan," 204 innovative drugs and 265 innovative medical devices have been approved, with 50 drugs approved in the first seven months of 2023 [17]. - A comprehensive service network has been established to guide enterprises through the drug development process, aiming for a 30-day review period for key innovative drugs [18]. - By 2025, the approval process for innovative drugs is expected to reach a high-speed phase, with approval times comparable to international standards [18][19].